GLP-1 Liquid Drops are a type of intestinal insulinotropic hormone secreted by intestinal L cells, consisting of 30 or 31 amino acids. The half-life of natural GLP-1 is only 2 minutes, as it is easily degraded by dipeptidyl peptidase-4 (DPP-4). It adopts sublingual administration technology, directly absorbed into the bloodstream through the mucosa, bypassing the first pass effect, and its bioavailability is 3-5 times higher than oral tablets. The core ingredient is usually an improved formula of semaglutide or liraglutide, combined with penetration enhancers (such as kaempferol) to enhance mucosal penetration. It reduces the risk of major cardiovascular events by 20% by improving endothelial function and reducing oxidative stress (LEADER trial data). It can also reduce intrahepatic fat deposition and increase the fibrosis improvement rate by 2 times in NASH patients (non-alcoholic steatohepatitis study). Delay the progression of diabetes nephropathy, and slow down the decline rate of eGFR by 30% (FLOW test).
|
|
|
GLP-1 COA
GLP-1 Liquid Drop as Chemical Perturbers at the Interface of Saliva and Oral Microbiome: Unpredictable Local Niche Effects and Systemic Ripples
GLP-1, as an important intestinal insulinotropic hormone, has made significant progress in the treatment of metabolic diseases since its discovery. The traditional GLP-1 receptor agonist is mainly administered by injection, which shows good efficacy in the treatment of type 2 diabetes and obesity. However, as research deepens, scientists gradually discover that the role of GLP-1 is not limited to regulating blood sugar and weight, but may also have wide-ranging effects on other systems and organs in the human body. GLP-1 Liquid Drops, as a novel form of medication, enter the human body through sublingual administration and first interact with saliva and oral microbiota. This unique mode of administration may trigger a series of unforeseen local and systemic effects.
The physiological effects and drug development of GLP-1
The physiological role of GLP-1
GLP-1 is a peptide composed of 30 amino acids secreted by L cells in the ileum and colon after feeding. It mainly participates in energy metabolism regulation through the following three ways:
Central appetite regulation: GLP-1 can pass through the blood-brain barrier and act on the feeding center of the hypothalamus, enhancing the satiety signal and transmitting the message "already full" to the brain, thereby reducing food intake.
Gastrointestinal motility regulation: GLP-1 can inhibit vagus nerve activity, delay gastric emptying rate, produce sustained satiety, and also smooth postprandial blood glucose fluctuations.
Promote insulin secretion: GLP-1 is glucose dependent and can promote insulin secretion when blood sugar levels rise, while simultaneously inhibiting glucagon secretion, thereby reducing blood sugar levels. This characteristic makes GLP-1 less likely to cause hypoglycemia while regulating blood sugar, which is a major advantage compared to insulin therapy.
Development of GLP-1 receptor agonists
Due to the extremely short half-life of natural GLP-1 in the body, only about 2 minutes, it is easily degraded by dipeptidyl peptidase-4 (DPP-4) and cannot be directly used as a drug. To overcome this challenge, scientists have developed GLP-1 receptor agonists that mimic the structure and function of natural GLP-1, extending its duration of action in vivo. At present, GLP-1 receptor agonists have been widely used in the clinical treatment of type 2 diabetes and obesity. According to the characteristics of molecular structure, they can be divided into the following categories:
Substances extracted and improved from the saliva of venomous lizards, such as exenatide, lisinopide, etc. The amino acid sequences of these drugs have low homology with human GLP-1, but after structural changes, they can resist the degradation of DPP-4, thereby exerting the effect of intestinal insulinotropic and having hypoglycemic effects.
Second generation GLP-1 receptor agonists: In order to further improve the stability and prolong the half-life of drugs, scientists have developed second-generation GLP-1 receptor agonists such as liraglutide, benazepril, exenatide sustained-release microspheres, liraglutide, dulaglutide, and polyethylene glycol loxenapeptide. These drugs mainly bind to serum albumin or polyethylene glycol in the human body, reducing the chance of being broken down by DPP-4, thereby increasing molecular size and water solubility, and reducing injection frequency.
Third generation GLP-1 receptor agonists: including dual agonists formed by binding to GIP (insulin-like growth factor), such as tilpotide, and orally administered semaglutide. These drugs can simultaneously activate two receptors, providing superior clinical efficacy, and are administered in a more convenient and comfortable manner.
Unique administration mode and mechanism of action of GLP-1 Liquid Drops
product key technologies
Sublingual administration method
GLP-1 Liquid Drop use sublingual administration technology, directly absorbed into the bloodstream through the mucosa, bypassing the first pass effect and greatly improving bioavailability. Compared with traditional injection administration methods, sublingual oral administration has the advantages of non invasiveness, convenience, and high patient compliance. For patients who have a fear of injections, such as injection phobia patients, as well as elderly and pediatric patients, GLP-1 Liquid Drop provide a more feasible treatment option.
Mechanism of action in the oral cavity
When GLP-1 Liquid Drop are administered sublingually, the drug components first come into contact with saliva. Saliva contains various proteins, enzymes, and microorganisms that may interact with GLP-1, affecting its stability and activity. Meanwhile, GLP-1 may also have an impact on salivary proteomics, altering the levels of certain proteins or metabolites in saliva. For example, GLP-1 may affect the composition and flow of saliva by regulating the secretion function of salivary gland cells.
In addition, there is a rich microbial community in the oral cavity, which is closely related to human health. GLP-1 Liquid Drops entering the oral cavity may act as chemical disruptors, altering the composition and function of the oral microbiome. On the one hand, GLP-1 may directly inhibit the growth and reproduction of certain harmful bacteria, or promote the growth of beneficial bacteria, thereby regulating the balance of oral microbiota; On the other hand, GLP-1 may indirectly affect the survival and metabolism of oral microorganisms by affecting the oral environment, such as altering the pH value and redox potential of saliva.
Potential impact on oral microbiome
Composition and function of oral microbiome
The oral microbiome is one of the five major microbial libraries in the human body, containing hundreds of types of bacteria, fungi, viruses, and other microorganisms. These microorganisms form complex biofilms in the oral cavity, which are closely related to oral and overall health. The oral microbiome not only participates in the digestion and absorption of food, but also plays an important role in the immune defense of oral mucosa, mineralization and demineralization of teeth, and other processes. Meanwhile, the imbalance of the oral microbiome is closely related to the occurrence and development of various oral diseases, such as dental caries, periodontitis, bad breath, etc. In addition, more and more studies have shown that oral microbiome is also associated with systemic diseases, such as diabetes, cardiovascular disease, respiratory disease, kidney disease, etc.
Direct effects of GLP-1 Liquid Drop on oral microbiome
GLP-1 receptors are not only present in the pancreas, gastrointestinal tract, and other areas, but also widely distributed in immune cells (such as T cells, macrophages) and skin tissues. Although there is currently relatively little research on the expression of GLP-1 receptors in oral microbiota, it can be speculated that GLP-1 may directly regulate the growth and metabolism of oral microbiota by binding to receptors on the surface of oral microbiota or affecting their metabolic pathways. For example, GLP-1 may inhibit the growth of certain acid producing bacteria, reduce acid production in dental plaque, and thus lower the risk of dental caries; Or promote the growth of probiotics with anti-inflammatory effects and alleviate oral inflammatory reactions.
Indirect effects of GLP-1 Liquid Drop on oral microbiome
The indirect effect of GLP-1 Liquid Drop on the oral microbiome is mainly achieved by altering the oral environment. GLP-1 can regulate the secretion function of salivary glands, affecting the composition and flow of saliva. Saliva contains various antibacterial substances, such as lysozyme, immunoglobulin, etc., and the content and activity of these substances may be regulated by GLP-1. When GLP-1 increases the secretion of antibacterial substances in saliva, it can enhance the oral antibacterial ability and inhibit the growth of harmful bacteria. In addition, GLP-1 may also affect the interaction between oral microbiota and the host by regulating the immune function of the oral mucosa. For example, GLP-1 may enhance the barrier function of oral mucosa, reducing microbial invasion and infection.
Unforeseen local niche effects
Effects on Oral Mucosa
GLP-1 Liquid Drop may have direct or indirect effects on oral mucosa in the oral cavity. On the one hand, drug ingredients may stimulate the oral mucosa, causing local inflammatory or allergic reactions. For example, a small number of patients may experience discomfort symptoms such as oral mucosal pain, redness, and swelling after using GLP-1 receptor agonists. On the other hand, GLP-1 may have a positive impact on the health of oral mucosa by regulating its immune function and metabolic status. Research has shown that GLP-1 has anti-inflammatory and immunomodulatory effects, which may alleviate the inflammatory response of oral mucosa and promote its repair and regeneration.
Effects on teeth
The imbalance of the oral microbiome is one of the main causes of dental diseases such as dental caries and periodontal disease. GLP-1 Liquid Drop may have a positive impact on dental health by regulating the composition and function of the oral microbiome. As mentioned earlier, GLP-1 may inhibit the growth of acid producing bacteria, reduce the production of acid in dental plaque, and thus lower the risk of dental caries. In addition, GLP-1 may promote the repair and regeneration of periodontal tissue, alleviating symptoms of periodontitis. For example, GLP-1 may promote the proliferation and differentiation of periodontal ligament cells, enhance the adhesion and stability of periodontal tissue by regulating the expression of cytokines and growth factors in periodontal tissue.
Effects on Saliva Secretion and Composition
GLP-1 Liquid Drop may affect the secretion function of salivary glands, altering the secretion volume and composition of saliva. On the one hand, GLP-1 may stimulate salivary gland cells to secrete more saliva, increase oral moisture, and alleviate dry mouth symptoms. On the other hand, GLP-1 may regulate the levels of various components in saliva, such as proteins, enzymes, electrolytes, etc. For example, GLP-1 may increase the secretion of antibacterial substances in saliva, enhancing the oral antibacterial ability; Or adjust the content of buffering substances in saliva to maintain the stability of oral pH value.
Hot Tags: glp-1 liquid drops, suppliers, manufacturers, factory, wholesale, buy, price, bulk, for sale